RxDoctor Payments Data

Heather Thorpe

Family · Jacksonville, FLNPI 1942536719

Payments from drug & device makers

$10,881in general payments, 2019–2025

Across 126 payments — averaging $86.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$4K
  • Boston Scientific$2K
  • Medtronic$2K
  • Abbott$774
  • Abiomed$593
  • Biosense Webster, Inc.$293
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$4,92345%
  • Food & beverage$5,86654%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,881 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$17,349
Medicare patients
155
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban359$369,660
MultaqDronedarone Hcl43$52,930
EntrestoSacubitril/Valsartan51$51,500
XareltoRivaroxaban58$50,660
Metoprolol Succinate168$2,270
Flecainide Acetate59$2,139
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$1,747
Amiodarone Hcl127$1,686
SotalolSotalol Hcl52$1,108
Carvedilol80$532
Metoprolol Tartrate84$481
Digoxin13$179
Amlodipine Besylate42$128
Warfarin Sodium20$127
Furosemide31$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$138$52,93043 claims
NovartisEntresto$44$51,50051 claims
Johnson & JohnsonXarelto$58$50,66058 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →